Sermorelin for women
Sermorelin for Women: Benefits, Studies and Buying Questions
Sermorelin for women has been studied, but the findings do not support every benefit advertised online. A six-month trial of sermorelin included older women and found improvements on selected cognitive tests. A separate trial used a modified analogue and found that several benefits seen in men did not appear in women. Neither establishes a treatment for menopause symptoms or predicts what a current compounded prescription will do for you. Before paying, match the claim to the exact drug, the women studied and the outcome measured. Use the table below to check whether a clinic's claim matches its evidence.
Connects studies that included women with the drug, measured outcome and prescription questions that matter before choosing care. It is a bounded source review, not a systematic review or individual medical advice.
Were women studied?
Yes, including a six-month sermorelin trial
Do all GHRH studies apply?
No. The molecule and outcome must match
Before choosing a plan
Check the evidence and the full payment terms
Swipe the evidence table sideways to read every column.
| Study and exact drug | Participants and duration | What the findings mean for women |
|---|---|---|
| Vitiello, 2006: sermorelin acetate (Geref) | 100 randomized; 89 completed, including 54 women. Six months; placebo controlled | Selected cognitive-test results favored treatment. The analysis found no clear difference in the treatment effect by sex or estrogen use; it cannot confirm equal effects in every subgroup |
| Khorram, 1997: [Nle27]GHRH(1-29), a modified analogue | 10 women and 9 men, ages 55 to 71. Four weeks of placebo followed by 16 weeks of treatment | Skin thickness increased in both sexes. Lean mass, insulin sensitivity, well-being and libido improved only in men; body weight and sleep quality were unchanged |
| Baker, 2012: tesamorelin | 152 older adults, including people with mild cognitive impairment. Twenty weeks; placebo controlled | Reported cognitive effects concern tesamorelin, a different drug. This trial cannot establish benefits of a sermorelin prescription |
What benefits of sermorelin have been studied in women?
The six-month Vitiello trial tested actual sermorelin acetate. Of its 54 female completers, 27 received the drug and 27 received placebo. Results on tests including performance IQ and picture arrangement favored treatment, but the authors left their clinical meaningfulness unresolved. The analysis did not detect a difference by sex or estrogen status; that is not proof of equal benefit in every subgroup. The manufacturer supplied the drug and placebo, and two authors disclosed commercial ties.
Read each benefit separately. The modified analogue used in 1997 raised growth hormone in women, but several other outcomes did not improve. The table shows which results changed and which stayed the same.
Does sermorelin help women lose weight or build muscle?
The 16-week analogue study does not support that promise. Body weight was unchanged, and the lean-mass gain reported in men was not seen in women. Ten women is a small group, so this result cannot settle what happens in every population. It also cannot justify advertising the men's result as a women's benefit.
When a clinic cites fat loss, check the drug name and the participants before comparing percentages. Studies of tesamorelin or other treatments do not establish what sermorelin will do for weight or body composition.
Can sermorelin treat menopause symptoms or brain fog?
The studies here do not establish that use. Performance on a cognitive test is a different outcome from relief of menopause-related brain fog, hot flashes or vaginal symptoms. A study including older women does not automatically become a menopause-treatment trial.
Geref's historical FDA indications concerned growth failure in children with growth-hormone deficiency and diagnostic evaluation of the pituitary gland. Those approvals did not cover menopause care. If that is the question you want answered, our sister site HRT Picks compares menopause-care services and their costs.
What can sermorelin before-and-after photos tell women?
They cannot tell you whether a study's result applies to you. For example, the analogue trial measured skin thickness at the hands and forearms. That is not a measured improvement in facial wrinkles or a validated cosmetic transformation.
Ask what a picture is supposed to demonstrate, whether the same outcome was assessed in women and what else changed during that period. A photograph cannot separate the effects of treatment from lighting, skincare, exercise or other changes. Use it as a reason to ask for evidence, not as a promised result.
Do these sermorelin studies apply to tablets or nasal sprays?
The studies in the table used injections. They do not establish that a current tablet, dissolvable product or nasal spray has the same effect. A shared drug name is only one part of the comparison; formulation and route matter too.
Ask the prescriber for evidence that matches the product offered. Before comparing prices across formats, confirm the ingredient, strength, amount supplied and refill term. A cheaper listing may represent a different prescription rather than a lower price for the same treatment.
What safety questions should women raise before treatment?
Ask who will assess your medical history, medicines, pregnancy plans and breastfeeding, and which pharmacy will dispense the exact prescription. FDA does not review compounded drugs for safety, effectiveness or quality before marketing. Evidence for a historical finished product does not verify a current compounded preparation.
Pregnancy and breastfeeding need a specific conversation before treatment. The historical Irish Geref 50 product information says that diagnostic injection should not be used during pregnancy or lactation. This is Irish labeling revised in 2004, not a current US label for a compounded prescription. The adult studies above do not establish safety during pregnancy or breastfeeding.
A provider should also explain whom to contact about a reaction and how treatment will be reassessed. A short study cannot establish every long-term risk, and a list of possible benefits is not a substitute for that discussion.
- Vitiello et al.: six-month sermorelin cognition trial, 2006; primary full text
- PubMed: Khorram et al., modified GHRH analogue trial in older women and men, 1997
- PubMed: Baker et al., tesamorelin cognition trial in older adults, 2012
- FDA: understanding the risks of compounded drugs
- HPRA: historical Irish Geref 50 product information, text revised May 2004
What should I ask before paying for a sermorelin plan?
What change are we trying to achieve? Ask the clinician to name the outcome and explain how it would be assessed. A laboratory result and a change in how you feel answer different questions.
Which evidence supports this exact prescription? The answer should identify the drug, route and people studied. Use the table above to check whether the cited finding concerns women, a modified analogue or a different medication.
What is the complete payment commitment? Request the initial charge, next charge, amount supplied and any required fees. A monthly average within a prepaid term does not tell you how much is due today.
What happens if the prescription is unsuitable or treatment does not help? Ask about the clinician's reassessment process and the written cancellation and refund terms. A transparent plan helps you understand the commitment; it does not guarantee a health result.
Where can I compare current sermorelin providers?
The pages below compare public product and contract information. Some are labeled partner links. Any commission we receive does not change evidence claims or table order.
Partner link; we may earn a commission. Editorial order and findings do not change.
Compounded; not FDA-approved. Prescription required only if a licensed provider finds it appropriate.
Which sources support this answer?
Sources were checked October 13, 2026. They define the product, population and evidence limits used above; they do not determine individual suitability.
- Vitiello et al.: six-month sermorelin cognition trial, 2006; primary full text
- PubMed: Khorram et al., modified GHRH analogue trial in older women and men, 1997
- PubMed: Baker et al., tesamorelin cognition trial in older adults, 2012
- FDA: historical Geref indications and discontinued-product determination, 2013
- FDA: understanding the risks of compounded drugs
- HPRA: historical Irish Geref 50 product information, text revised May 2004
These are products marketed in the longevity category, not established lifespan-extension treatments. Compounded drugs are not FDA-approved. This publication compares public information; a clinician must assess individual suitability. How we compare.